Table of Content

1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Increasing Prevalence of Infectious Diseases
4.2.1.2. Increasing Funding for Research Activities
4.2.1.3. Growth in Proteomics and Genomics Research Studies
4.2.1.4. Growing Number of Clinical Laboratories Offering Advanced Diagnostic Testing Menus
4.2.2. Restraints
4.2.2.1. Stringent Regulations for Antigen-Specific Reagents
4.2.3. Opportunities
4.2.3.1. Growing Demand for Protein Therapeutics and Personalized Medicines
4.2.3.2. Emerging Economies
4.2.4. Challenges
4.2.4.1. High Costs of Reagents and the Unfavorable Reimbursement Scenario
4.2.5. Factor Analysis
4.3. Regulatory Analysis
4.3.1. U.S.
4.3.2. Canada
4.3.3. Europe
4.3.4. China
4.3.5. Japan
4.3.6. India
4.3.7. Latin America
4.3.8. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Buyers
4.4.2. Bargaining Power of Suppliers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
4.5. Pricing Analysis

5. In Vitro Diagnostic (IVD) Reagents Market Assessment?by Type
5.1. Overview
5.2. Antibodies
5.2.1. Antibodies Market, by Type
5.2.1.1. Monoclonal Antibodies
5.2.1.2. Polyclonal Antibodies
5.2.2. Antibodies Market, by Target
5.2.2.1. Cluster of Differentiation (CD)
5.2.2.2. T-Cell Receptor (TCR)
5.2.2.3. Epidermal Growth Factor Receptor (EGFR)
5.2.2.4. Other Targets
5.3. Purified Proteins and Peptides
5.4. Oligonucleotides
5.5. Nucleic Acid Probes
5.6. Other IVD Reagents

6. In Vitro Diagnostic (IVD) Reagents Market Assessment?by Technology
6.1. Overview
6.2. Immunoassay/Immunochemistry
6.2.1. Enzyme-Linked Immunosorbent Assays (ELISA) and Enzyme-Linked Immunospot Assays (ELISpot)
6.2.2. Lateral Flow Assays/Rapid Tests
6.2.3. Western Blotting
6.2.4. Immunofluorescence (IF)
6.2.5. Functional Assays
6.2.6. Immunoprecipitation
6.2.7. Other Immunoassay Technologies
6.3. Biochemistry/Clinical Chemistry
6.4. Molecular Diagnostics
6.4.1. Polymerase Chain Reaction (PCR)
6.4.2. Hybridization
6.4.3. Isothermal Nucleic Acid Amplification Technology
6.4.4. DNA Sequencing & Next-generation Sequencing
6.4.5. Microarrays
6.4.6. Other Molecular Diagnostic Technologies
6.5. Microbiology
6.6. Hematology
6.7. Coagulation/Hemostasis
6.8. Urinalysis
6.9. Other IVD Technologies

7. In Vitro Diagnostic Reagents Market Assessment?by Use
7.1. Overview
7.2. Clinical Use
7.3. Research Use Only (RUO)
7.4. Analyte-Specific Reagents (ASR)

8. In Vitro Diagnostic Reagents Market Assessment?by End User
8.1. Overview
8.2. IVD Manufacturers
8.3. Reference Laboratories
8.4. Academic Institutes & Research Laboratories
8.5. Hospital Laboratories

9. In Vitro Diagnostic Reagents Market Assessment?by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Switzerland
9.3.7. Netherlands
9.3.8. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. South Korea
9.4.5. Australia
9.4.6. Singapore
9.4.7. Rest of Asia-Pacific
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
9.6. Middle East & Africa

10. Competition Analysis
10.1. Overview
10.2. Competitive Benchmarking
10.3. Competitive Dashboard
10.3.1. Industry Leaders
10.3.2. Market Differentiators
10.3.3. Vanguards
10.3.4. Emerging Companies
10.4. Market Share Analysis (2022)
10.4.1. Thermo Fisher Scientific (U.S.)
10.4.2. Merck KGaA (Germany)
10.4.3. Becton, Dickinson and Company (U.S.)

11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1. Thermo Fisher Scientific Inc.
11.2. Becton, Dickinson and Company
11.3. Bio-Rad Laboratories, Inc.
11.4. Agilent Technologies, Inc.
11.5. QIAGEN N.V.
11.6. Merck KGaA
11.7. Beckman Coulter, Inc. (A subsidiary of Danaher Corporation)
11.8. Hologic, Inc.
11.9. Abcam Plc.
11.10. Bio-Techne Corporation
11.11. Bio-Synthesis Inc.
11.12. Raybiotech, Inc.
11.13. SDIX, LLC. (A subsidiary of Origene Technologies, Inc.)
11.14. Sino Biological Inc.
11.15. Oy Medix Biochemica Ab
11.16. InBios International, Inc.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

12. Appendix
12.1. Available Customization
12.2. Related Reports



List of Figures

Figure 1 Research Process
Figure 2 Secondary Sources Referenced for this Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global IVD Reagents Market, by Type, 2023 Vs.2030 (USD Million)
Figure 8 Global IVD Reagents Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 9 Global IVD Reagents Market, by Use, 2023 Vs. 2030 (USD Million)
Figure 10 Global IVD Reagents Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 11 Global IVD Reagents Market, by Geography
Figure 12 Impact Analysis: IVD Reagents Market
Figure 13 U.S.: Share of Medical and Health R&D Expenditure, by Organization Type, 2020
Figure 14 Global Pharmaceutical R&D Expenditure, 2016–2024 (USD Billion)
Figure 15 Estimated Number of New Cancer Cases, by Region, 2020 Vs. 2030
Figure 16 USFDA Regulatory Pathways for IVD Reagents
Figure 17 Eu Regulatory Pathway - IVD r 2017/746
Figure 18 Porter’s Five Forces Analysis
Figure 19 Global In-Vitro Diagnostic Reagents Market, by Type, 2023 Vs. 2030 (USD Million)
Figure 20 Global In-Vitro Diagnostic Reagents Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 21 Global In-Vitro Diagnostic Reagents Market, by Use, 2023 Vs. 2030 (USD Million)
Figure 22 Global In-Vitro Diagnostic Reagents Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 23 Global In Vitro Diagnostic Reagents Market, by Region, 2023 Vs. 2030 (USD Million)
Figure 24 North America: Healthcare Expenditure (% of GDP), 2015?2020
Figure 25 North America: IVD Reagents Market Snapshot
Figure 26 Canada: Number of People Aged 65 and above, 2018?2022 (In Million)
Figure 27 Europe: In Vitro Diagnostic Reagents Market Snapshot
Figure 28 France: Number of People Aged 65 Years and above, 2017?2022 (Millions)
Figure 29 U.K.: Number of Cancer Cases, 2020?2040 (In Millions)
Figure 30 U.K.: Number of People Diagnosed with Sexually Transmitted Infections, 2018?2020 (In Thousands)
Figure 31 Italy: Ovarian Cancer Cases (2020?2040)
Figure 32 Spain: Number of HIV Tests Performed in Catalonia (Spain), 2017?2021
Figure 33 Switzerland: Number of People Aged 65 Years and above, 2018?2022
Figure 34 Netherlands: Number of People Aged 65 Years and above, 2017?2022
Figure 35 Rest of Europe: Healthcare Expenditure (2015 Vs 2020)
Figure 36 Asia-Pacific: In Vitro Diagnostic Reagents Market Snapshot
Figure 37 Japan: Percentage Share of The Geriatric Population (Aged 65 Years and above) (2018?2022)
Figure 38 India: Number of People Aged 65 Years and above, 2018-2022 (% of Total Population)
Figure 39 Latin America: Number of People Aged 65 Years and above, 2015-2022 (In Millions)
Figure 40 Latin America: In Vitro Diagnostic Reagents Market Snapshot
Figure 41 Brazil: Prevalence of Diabetes, 2000?2045, (In Thousands)
Figure 42 IVD Reagents Market: Competitive Benchmarking (Based on Type)
Figure 43 IVD Reagents Market: Competitive Benchmarking (Based on Use)
Figure 44 IVD Reagents Market: Competitive Benchmarking (Based on Geography)
Figure 45 Competitive Dashboard: IVD Reagents Market
Figure 46 Global IVD Reagents Market Share Analysis, by Key Players, 2022 (%)
Figure 47 Thermo Fisher Scientific Inc.: Financial Snapshot (2022)
Figure 48 Becton, Dickinson and Company: Financial Snapshot (2022)
Figure 49 Bio-Rad Laboratories, Inc.: Financial Snapshot (2022)
Figure 50 Agilent Technologies, Inc.: Financial Snapshot (2022)
Figure 51 QIAGEN N.V.: Financial Snapshot (2022)
Figure 52 Merck KGaA: Financial Snapshot (2022)
Figure 53 Danaher Corporation: Financial Snapshot (2022)
Figure 54 Hologic, Inc.: Financial Snapshot (2022)
Figure 55 Abcam Plc.: Financial Snapshot (2022)
Figure 56 Bio-Techne Corporation: Financial Snapshot (2022)